Navigation Links
Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComm's CRO Preferred Program
Date:8/18/2009

reaches clients worldwide through its Internet-based data collection and reporting capabilities. Amarex is headquartered in Germantown, MD. For more information, please visit the company's Web site at http://www.amarexcro.com.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any finan
'/>"/>

SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
3. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
4. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
5. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
6. Radius Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
7. Project Zero Delay Accelerates Drugs Path to Clinical Trial
8. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
9. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
10. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...rdingtoMillenniumResearchGroup(MRG),theglobalautho...y$3billionUSmarketfortraumafixationdeviceswillcont...recenteconomicslowdown.MRG,s USMarketsforTraumaDev...lydynamicoverthenextfiveyears,withcompetitorsintro...mentsofthetraumafixationmarket,fuelingmarketgrowth...
(Date:11/25/2009)...er.comannouncesthatanewmarketresearchreportisavail...USMarketTrends&Analysis http://www.reportlink...et-Trends--Analysis.html ,, TheUSintranasaldru...capplicationsfromthedeliveryofconventionallocalthe...gs.Thefutureofthetechnologyhingesontotheeffectivee...
(Date:11/24/2009)...ChindexInternational,Inc.,("Chindex")(Nasdaq: CHDX...althcareproductsandservicesinthePeople,sRepublicof...stAnnualPiperJaffray,"Unplugged"HealthCareConferen...el. , Managementiscurrentlyscheduledtopresent...-onemeetingsthroughouttheday.Awebcast,ofthepresent...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 1Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 2Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 3Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 1Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 2Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 3Study shows link between influenza virus and fever 10734 1Study shows link between influenza virus and fever 10734 2
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceutica...willhosttwoinvestoreventsinDecember: ,, ASHBr...m.ET ,, Principalinvestigatorswilldiscussdata...rrefractorymultiplemyeloma,asfeaturedatthe51stAmer...tioninNewOrleans,LA.Theteleconferencewillbeginat9:...
(Date:11/25/2009).../PRNewswire-USNewswire/--TheBlackAIDSInstituterece...veleadershipfor2010. ,, ThenewBoardMembersareah...olicy,law,finance,governmenthealthprograms,editori...omawiderangeofpersonalbackgroundsincludingbothhete...emselves,andrepresentingmultipleagegroups. ,, (...
(Date:11/25/2009)...y that grew out of a collaboration between UCLA en...e to the nearly 10 million Americans who suffer fr... as hardening of the arteries, peripheral arterial...in which narrowed arteries reduce blood flow to th...r vascular disease, heart attack and stroke, and i...
(Date:11/25/2009)...uld lead mothers to overlook needed care, study fi...ws) -- A mother,s depression can worsen her child,...six-month study of 262 black mothers and their chi...epressive symptoms had more frequent asthma sympto...e symptoms had less frequent asthma symptoms. ,...
(Date:11/25/2009)...ntShownforthe4thStraightYear ,, WASHINGTON,No...iance-Georgia(LCA-GA)issuedthe 4thAnnualReportCard...ingmadeagainstthislethaldiseaseinthestateofGeorgia...nationalorganizationdedicatedexclusivelytopatients...gcancer. ,, (Logo: http://www.newscom.com/cgi-b...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
..., SWITZERLAND, March 13 /PRNewswire-FirstCall/ - N...olly-owned subsidiary of Neurochem,Inc. (NASDAQ: ...king new,initiatives to pursue the drug developmen...s. Neurochem,s decision to build,upon its eprodisa...
...y Outlines Milestones for 2008 -, EMERYVILLE, Cal...y announced financial results for the fourth quart... Quarter Results, The company reported revenues f...riod in 2006, is due primarily,to the recognition ...
... results of combination therapy VELCADE, melphalan...mission rate with 85 percent of patients ... Mass., March 13 Millennium,Pharmaceuticals, Inc....d prednisone (VcMP) in newly diagnosed multiple,my...
...ntone Hosts Fundraiser, NEW YORK, March 13 DKMS ...awford at their "Linked Against Leukemia Gala" on,...ity. The 2nd annual,black-tie affair is a benefit ...te more than 13,000 transplants., The evening wil...
...ured majority of convertible notes due June 2008 ...orward Projects Zevalin(R) net sales revenues ...e-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MT...ompletion of Zevalin(R) (Ibritumomab Tiuxetan) acq...
...UVER Shining synchrotron light on environmental q... a Memorandum of Understanding (MOU) signed today ...Light Source (CLS) and MIRARCO Mining Innovation. ...his collaboration will undoubtedly be of tremendou...
Other Medicine News:Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Bionovo Announces 2007 Financial Results and Highlights 2Health News:Bionovo Announces 2007 Financial Results and Highlights 3Health News:Bionovo Announces 2007 Financial Results and Highlights 4Health News:Bionovo Announces 2007 Financial Results and Highlights 5Health News:Bionovo Announces 2007 Financial Results and Highlights 6Health News:Bionovo Announces 2007 Financial Results and Highlights 7Health News:Bionovo Announces 2007 Financial Results and Highlights 8Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Super Model Cindy Crawford will be Honored at DKMS 'Linked Against Leukemia Gala' on May 7th at Capitale 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:MIRARCO, Canadian Light Source agreement lights way to greener mining 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: